

Lenbach Equity Opportunities III. GmbH & Co. KG signed a purchase agreement for BioNTech's peptide business JPT Peptide Technologies GmbH

Munich/Mainz/Berlin, August 21, 2026 – Lenbach Equity Opportunities III. GmbH & Co. KG (“LEO III Fund”), a private equity fund advised by the DUBAG Group, has signed an agreement with BioNTech Diagnostics GmbH, a wholly owned indirect subsidiary of BioNTech SE, to acquire all shares in JPT Peptide Technologies GmbH (“JPT”), Berlin. This divestiture is part of BioNTech’s strategic focus on its core business to become a multi-product biopharmaceutical company by 2030.

Founded in 2004 as a spin-off from Jerini AG and part of BioNTech since 2009, JPT is one of the leading international providers of peptide-based research and development solutions. From its Berlin site, the company offers custom peptide synthesis across all scales and complexities, peptide libraries, pools, and microarrays under its established PepTrack™, PepMix™ and PepStar™ brands, proteomics standards as well as critical raw material and pre-GMP peptides, complemented by bioassay and analytics services such as epitope mapping and antibody profiling. Built on its proprietary ultra-high-throughput SPOT synthesis technology, JPT serves more than 20,000 customers in over 100 countries across biopharma, cell and gene therapy, vaccine development, immunology, proteomics and academic research. The company has been ISO 9001 certified since 2004 and employs approx. 130 people.

Strategic realignment of JPT following ownership change

Following the transaction, JPT will continue its business as an independent, technologically leading and internationally operating solution provider for custom peptide synthesis and peptide-based reagents. The focus is on the development, manufacturing, and sales of comprehensive peptide solutions that go beyond the mere delivery of catalog products. As a stand-alone company, JPT will continue to invest consistently in capacity, technology leadership, quality, and speed.

The company's growth strategy is focused on the European and North American markets. In Europe, JPT aims to build further on its established position and scientific reputation, while in North America it looks to expand its commercial footprint and local application support. Over the last 20 years, JPT has built its renown on its unique peptide manufacturing platform combining immense capacities, a large diversity of technical solutions, proprietary products

and processes, and uncompromised quality and customer satisfaction. Under the ownership of the LEO III Fund, JPT will continue to accelerate its international development, pursue its portfolio diversification and enforce its operational efficiency. Customers will continue to benefit not only from high-purity custom peptides but also from extensive application support, assay development, peptide library design and contract manufacturing services covering the entire value chain.

Sebastian Stalter, Director at the DUBAG Group, comments:

“JPT is an outstanding company with world-class peptide expertise and a loyal international customer base. We very much look forward to working with Aurélien Claeysen, his management team and the entire team, and to jointly positioning JPT for growth in Europe and North America. JPT will continue to invest in its technology platform and align its products and services even more closely to customer needs. We would like to thank BioNTech for a trusted and constructive process.”

Sierk Poetting, Ph.D., Chief Operating Officer at BioNTech, adds:

“This transaction is an excellent outcome of the strategic review process we initiated following our decision to optimize our manufacturing capacities in response to the reduced demand for COVID-19 vaccines and our continued focus on advancing our pipeline and becoming a multi-product biopharmaceutical company by 2030. We would like to thank DUBAG Group for the constructive and collaborative partnership throughout this process and for their shared commitment to ensuring a smooth transition of JPT’s business and safeguarding the highly skilled team. We wish Aurélien and the JPT team the best of success for their next chapter.”

Aurélien Claeysen, Managing Director of JPT Peptide Technologies, adds:

“The agreement represents a fantastic opportunity for JPT, its approximately 130 employees, and its customers. It ensures continuity for the company under new ownership while bringing opportunity for future development. JPT has an important role in the life sciences industry, and we are looking forward to building on that strong foundation with confidence.”

The completion of the transaction is subject to the fulfillment of certain contractually agreed conditions.

About BioNTech SE

BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

About DUBAG Group and LEO III. Fund

DUBAG Group, founded in 2009 and based in Munich, is a rapidly growing investment firm managing the private equity fund Lenbach Equity Opportunities III. GmbH & Co. KG ("**LEO III Fund**"), which invests in mid-cap companies facing special situations such as corporate carve-outs, turnarounds, succession issues in family-owned businesses, complex financing structures, and tail-end situations for financial investors. The LEO III Fund follows a pan-European investment strategy, with particular focus on the DACH region and Italy.

For further information, please contact:



Sebastian Stalter
Director

DUBAG Group
Thomas-Wimmer-Ring 1,
80539 Munich

T. +49 89 45 209 45 – 0
E. contact@dubag.eu

